These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 25002322)

  • 21. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial.
    Yalcin S; Uslu R; Dane F; Yilmaz U; Zengin N; Buyukunal E; Buyukberber S; Camci C; Sencan O; Kilickap S; Ozdener F; Cevik D
    Oncology; 2013; 85(6):328-35. PubMed ID: 24247559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study.
    Rosati G; Avallone A; Aprile G; Butera A; Reggiardo G; Bilancia D
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):257-64. PubMed ID: 23100174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-line mono-chemotherapy in frail elderly patients with metastatic colorectal cancer.
    Varol U; Dirican A; Yildiz I; Oktay E; Degirmenci M; Alacacioglu A; Barutca S; Karabulut B; Uslu R
    Asian Pac J Cancer Prev; 2014; 15(7):3157-61. PubMed ID: 24815463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Novel methods of treatment for colorectal carcinoma: from oral chemotherapy to angiogenesis inhibitors].
    Longo F; Mansueto G
    Tumori; 2006; 92(1):suppl 1-15. PubMed ID: 16683391
    [No Abstract]   [Full Text] [Related]  

  • 25. Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.
    Whyte S; Pandor A; Stevenson M; Rees A
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):47-53. PubMed ID: 21047491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C.
    Price TJ; Zannino D; Wilson K; Simes RJ; Cassidy J; Van Hazel GA; Robinson BA; Broad A; Ganju V; Ackland SP; Tebbutt NC
    Ann Oncol; 2012 Jun; 23(6):1531-6. PubMed ID: 22039086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer.
    Muñoz A; Pericay C; García-Girón C; Alonso V; Dueñas R; Cirera L; Rivera F; Falcó E; Bustos IA; Salud A
    Oncol Res; 2013; 21(4):181-91. PubMed ID: 24762224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.
    Hong YS; Lee SS; Kim KP; Lee JL; Kang YK; Shin SJ; Ahn JB; Jung KH; Im SA; Kim TY; Kim JH; Park YS; Kim TW
    Am J Clin Oncol; 2014 Feb; 37(1):19-23. PubMed ID: 23111359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Baseline physical functioning status of metastatic colorectal cancer patients predicts the overall survival but not the activity of a front-line oxaliplatin-fluoropyrimidine doublet.
    Comella P; Casaretti R; Manzo R; Sandomenico C; Licenziato M; Avallone A; Franco L;
    Acta Oncol; 2010; 49(1):50-6. PubMed ID: 20100144
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients.
    Chen HH; Chen WT; Lee HC; Lin JK; Fang CY; Chou YH; Lin PC; Lin BW; Huang CC; Yeh CH; Hsu HH; Chen HC; Ting WC; Yang MC; Tan EC
    Qual Life Res; 2015 Feb; 24(2):473-84. PubMed ID: 25099199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
    Mitry E; Walter T; Baudin E; Kurtz JE; Ruszniewski P; Dominguez-Tinajero S; Bengrine-Lefevre L; Cadiot G; Dromain C; Farace F; Rougier P; Ducreux M
    Eur J Cancer; 2014 Dec; 50(18):3107-15. PubMed ID: 25454413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy in elderly patients with colorectal cancer.
    Köhne CH; Folprecht G; Goldberg RM; Mitry E; Rougier P
    Oncologist; 2008 Apr; 13(4):390-402. PubMed ID: 18448553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer.
    Matsusaka S; Suenaga M; Mishima Y; Takagi K; Terui Y; Mizunuma N; Hatake K
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):763-8. PubMed ID: 21170650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry.
    Slavicek L; Pavlik T; Tomasek J; Bortlicek Z; Buchler T; Melichar B; Vyzula R; Prausova J; Finek J; Majek O; Dusek L
    BMC Gastroenterol; 2014 Mar; 14():53. PubMed ID: 24666582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group.
    Hamaker ME; Seynaeve C; Wymenga AN; van Tinteren H; Nortier JW; Maartense E; de Graaf H; de Jongh FE; Braun JJ; Los M; Schrama JG; van Leeuwen-Stok AE; de Groot SM; Smorenburg CH
    Breast; 2014 Feb; 23(1):81-7. PubMed ID: 24314824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer.
    Puthillath A; Mashtare T; Wilding G; Khushalani N; Steinbrenner L; Ross ME; Romano K; Wisniewski M; Fakih MG
    Crit Rev Oncol Hematol; 2009 Sep; 71(3):242-8. PubMed ID: 19081732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
    Miller KD; Chap LI; Holmes FA; Cobleigh MA; Marcom PK; Fehrenbacher L; Dickler M; Overmoyer BA; Reimann JD; Sing AP; Langmuir V; Rugo HS
    J Clin Oncol; 2005 Feb; 23(4):792-9. PubMed ID: 15681523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of geriatric intervention in frail elderly patients receiving chemotherapy for colorectal cancer: a randomized trial (GERICO).
    Lund CM; Vistisen KK; Dehlendorff C; Rønholt F; Johansen JS; Nielsen DL
    BMC Cancer; 2017 Jun; 17(1):448. PubMed ID: 28659138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
    Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
    Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
    J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.